English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: The assessment of acute coronary syndrome (ACS) provides useful data not only for identification but also for therapeutic decisions. Objective: To develop a score based on cardiac biomarker for the early diagnosis of ACS patients. Methods: Serum concentrations of myeloperoxidase (MPO) and monocyte chemoattractant protein-1 (MCP-1) beside cardiac troponin I (cTnI) and creatine kinase MB (CK-MB) were measured in a total 200 chest pain patients represented in two groups (estimation and validation). The diagnostics value of biomarkers for discriminating ACS patients was evaluated by area under the receiver-operating characteristic curve (AUC). Multivariate discriminant analysis (MDA) was used to create a predictive score. Results: A novel score depends on a combination of cTnI, CK-MB, MPO, and MCP-1 produces AUCs of 0.93 for discriminating ACS patients and 0.90 for acute myocardial infarction (AMI). This score correctly classied 95% of ACS patients and 93% of AMI patients with good efficiencies were 88.3% and 81%; respectively. This score had similar results in the validation study. Conclusion: Four biomarkers in combination yield a novel score to help in the early and safe prediction of ACS and AMI.

The utility of biomarkers in the discrimination of acute coronary syndrome patients